Table 3.
Univariate analysis of PFS and OS
| Factors | PFS (months) | OS (months) | ||
|---|---|---|---|---|
| Median, (95% CI) | P | Median, (95% CI) | P | |
| Sex | 0.168 | 0.250 | ||
| Male | 8.00, (6.01–9.99) | 30.00, (24.44–35.56) | ||
| Female | 11.50, (10.16–12.84) | 38.00, (22.88–53.13) | ||
| Age | 0.790 | 0.530 | ||
| ≤ 60 years old | 10.40, (1.20–8.04) | 30.00, (26.35–33.65) | ||
| > 60 years old | 9.50, (6.96–12.04) | 32.50, (25.86–39.14) | ||
| Body mass index | 0.564 | 0.345 | ||
| ≤ 25 kg/m2 | 8.50, (5.79–11.21) | 30.00, (26.87–33.14) | ||
| > 25 kg/m2 | 10.40, (9.28–11.52) | 38.00, (25.067–50.93) | ||
| Smoke abuse | 0.751 | 0.133 | ||
| Yes | 9.50, (6.87–12.13) | 30.00, (27.61–32.38) | ||
| No | 10.40, (8.64–12.16) | 39.00, (27.19–50.81) | ||
| Serum CEA | 0.048 | 0.004 | ||
| ≤ 15 ng/ml | 11.50, (10.26–12.75) | 39.00, (30.30–47.69) | ||
| > 15 ng/ml | 7.50, (4.84–10.16) | 28.30, (22.85–33.75) | ||
| Primary tumor site | 0.151 | 0.201 | ||
| Colon | 11.00, (9.29–12.71) | 32.50, (29.50–35.49) | ||
| Rectum | 8.00, (5.65–10.35) | 30.00, (27.90–32.10) | ||
| Pathological classification | 0.015 | 0.000 | ||
| Low differentiated | 6.30, (4.45–8.15) | 23.00, (20.17–25.84) | ||
| Middle-High differentiated | 11.40, (9.77–13.03) | 39.00, (30.54–47.46) | ||
| TNM stage | 0.001 | 0.000 | ||
| Stage I-III | 11.50, (11.10–11.90) | 39.00, (31.95–46.05) | ||
| Stage IV | 6.00, (4.90–7.10) | 21.00, (17.94–24.06) | ||
| ECOG score | 0.671 | 0.504 | ||
| PS 0 | 10.40, (8.95–11.85) | 32.50, (27.62–37.38) | ||
| PS 1 | 9.50, (8.35–10.65) | 29.00, (20.18–37.82) | ||
| Number of LO | 0.000 | 0.000 | ||
| ≤ 2 LO | 11.50, (10.02–12.98) | 39.00, (29.33–48.67) | ||
| > 2 LO | 7.00, (4.65–9.35) | 23.00, (20.82–25.18) | ||
| Cumulative GTV per patient | 0.000 | 0.000 | ||
| ≤ 40 cm3 | 12.40, (11.31–13.49) | 45.95(38.25–53.66) | ||
| > 40 cm3 | 7.50, (5.77–9.23) | 28.30, (20.74–35.86) | ||
| System treatments | 0.356 | 0.000 | ||
| C + TT | 11.20, (10.10–12.30) | 40.00, (36.57–43.43) | ||
| C alone | 7.50, (4.32–10.68) | 28.40, (22.26–34.54) | ||
AFP alpha fetoprotein, BCLC Barcelona Clinic Liver Cancer, CI Confidence interval, ECOG Eastern Cooperative Oncology Group, OS overall survival, PFS progression free survival, PO Pulmonary oligometastases, C Chemotherapy, TT target therapy